Hampshire Trust Bank Selects ComplyAdvantage For Award-Winning AML Solution Suite
ComplyAdvantage, a global data technology company transforming financial crime detection, today announced that Hampshire Trust Bank (HTB), a specialist bank, focused on lending to UK businesses has selected the company’s award-winning anti-money laundering (AML) suite of solutions including Customer Screening and Onboarding, Adverse Information & Media, Transaction Monitoring and Transaction Screening.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005009/en/
Charles Delingpole, CEO and Founder of ComplyAdvantage (Photo: Business Wire)
Staffed by a team of lending experts HTB provides specialist business finance, mortgages and, award-winning savings accounts for individuals and businesses. Because of rapid and significant growth, HTB’s risk profile is changing as the firm’s client base expands into newer markets. This is why HTB elected to partner with ComplyAdvantage in order to build stronger, real-time AML capabilities with better control and scalability.
“HTB is serious about combating financial crime and maintains carefully monitored controls across the bank. As we sought to strengthen those controls we wanted a solution that would bring both resilience and efficiency”, said Nick Hawke, Chief Compliance Officer for HTB . “ComplyAdvantage represents a key step in maturity by consolidating all screening and transaction monitoring into a single hosted platform, which delivers a robust and reliable solution.”
Powered by ComplyData™, ComplyAdvantage’s hyperscale technology helps to uncover hidden risks throughout the customer lifecycle, helping banks like HTB to maintain the highest level of compliance oversight and integrity. This reduces dependence on manual review processes and legacy databases by up to 80% and improves how businesses like HTB screen and monitor clients and transactions.
"We are very proud to be selected by such a highly regarded bank as HTB,” said Charlie Delingpole, founder and CEO ComplyAdvantage. “Now, the HTB team can transact with trust and grow with confidence by using our state-of-the-art AML intelligence, tools and technology needed to combat the volume, velocity and complexity of today’s financial crimes.”
About ComplyAdvantage
ComplyAdvantage is the financial industry’s leading source of AI-driven financial crime risk data and detection technology. ComplyAdvantage’s mission is to neutralize the risk of money laundering, terrorist financing, corruption, and other financial crime. More than 500 enterprises in 75 countries rely on ComplyAdvantage to understand the risk of who they’re doing business with through the world's only global, real-time database of people and companies. The company actively identifies tens of thousands of risk events from millions of structured and unstructured data points every single day.
ComplyAdvantage has four global hubs located in New York, London, Singapore and Cluj-Napoca and is backed by Goldman Sachs, Ontario Teachers’, Index Ventures and Balderton Capital. Learn more at complyadvantage.com.
About Hampshire Trust Bank
Hampshire Trust Bank is a specialist bank, focused on lending to UK businesses. HTB also provides savings accounts to individuals and businesses. The bank is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority. For more information, please visit our website: www.htb.co.uk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005009/en/
Contact information
For ComplyAdvantage:
North America
Tim Donovan
+1.510.593.0064
Tim.Donovan@ComplyAdvantage.com
EMEA
Ben Goldsmith
+44.0.7788.295321
ben@goldsmithcomms.com
For HTB
Andrew Bullock
Head of Marketing & Communications
Tel: +44 (0) 20 7886 4722
Email: andrew.bullock@htb.co.uk
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 13:30:00 CEST | Press release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde
Sealing System launches: XIO – Intelligent Farming26.4.2024 12:17:00 CEST | Press release
XIO – Intelligent Farming, specializes in logistics systems for insect protein production. XIO is a new business unit within Sealing System A/S, one of the leading providers of automated end-of-line packaging lines in Scandinavia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240426832303/en/ Robotic solution handling Black Soldier Fly Larvae (Photo: Business Wire) “At Sealing System A/S, we believe that practical innovation is the engine of real-world change. With the establishment of, XIO - Intelligent Farming, we are setting new industry standards, emphasizing the importance of intralogistics in the field of insect protein production, and proudly leading the way.” Ole Jensen CEO, Sealing System A/S XIO – Intelligent Farming provides solutions serving various aspects of the insect production, including fully automatic logistics systems, comprehensive data tracking, transfer trolleys and shuttles, as well as robot systems